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Background: Immune modifications, including changes in interleukin (IL)-6 levels, have often 
been observed in major depressive disorder (MDD) during treatment with selective serotonin 
reuptake inhibitors (SSRIs) or the serotonin norepinephrine reuptake inhibitor (SNRI) venlafax-
ine. Nevertheless, no equivalent observation for the SNRI duloxetine has been made to date.
Method: Sixteen patients diagnosed with MDD and an actual major depressive episode 
according to DSM-IV criteria and 16 healthy controls entered a 6-week trial with duloxetine 
60 mg/day. All subjects (n = 32) were assessed using the Hamilton Depression Rating Scale 
(HAM-D), the Young Mania Rating Scale (YMRS), and were monitored for IL-6 levels both at 
baseline and at week 6. Blood samples for IL-6 levels were evaluated by ELISA.
Results: After 6 weeks of treatment, the mean total scores for HAM-D declined both in 
the depressed and control groups, while IL-6 modification showed an opposite trend both 
in depressed (12.38 ± 19.80 to 19.73 ± 18.94 pg/mL) and control subjects (12.25 ± 21.12 to 
17.63 ± 20.44 pg/mL), as did YMRS (ns), although none of the subjects switched to (hypo)mania. 
Of note, IL-6 levels increased significantly only in the responders subgroup (n = 9; P = 0.012).
Conclusion: The small sample size and weak design of this study limit the validity of our 
results, which should be regarded as preliminary only. Nonetheless, the trend of increasing IL-6 
levels observed in responder patients treated with duloxetine should prompt further controlled, 
extended studies with larger samples, with the specific aim of better assessing a putative 
differential role of norepinephrinergic antidepressant stimulation of serotonergic reuptake 
inhibition in determining modifications in IL-6 levels. Ideally, more accurate replication studies 
may contribute to further understanding of the complex interaction of mood, antidepressant 
response, and the immune system.
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Introduction
In recent years, an increasing number of investigations have explored the relationship 
between immune and neuroendocrine systems and different psychiatric conditions, 
especially mood and anxiety disorders, with the aim of improving our understanding 
their etiopathology and developing more effective therapeutic management.1
Neurotransmitters and hormones regulate major immune functions, such as antigen 
presentation, antibody production, activity, proliferation and traffic of lymphocyte, 
as well as the process of cytokines secretion, including modulation of T helper (Th) 1 
or Th2 cytokine responses.2 In the course of inflammatory processes, the activation 
of the stress system, through induction of a Th2 shift, protects the organism from 
systemic “overshooting” with Th1/pro-inflammatory cytokines.2 Under certain 
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conditions, however, stress hormones and the activation of 
the  corticotropin-releasing  hormone/substance P-histamine 
axis may actually promote inflammation, through induction 
of interleukin (IL)-1, IL-6, IL-8, IL-18, tumor necrosis 
factor (TNF)-alpha, and C-reactive protein production.2 
Investigations of immune  imbalances in the course of major 
depressive disorder (MDD) have  demonstrated higher serum 
concentration of some  cytokines such as IL-6 (a Th2-type 
cytokine), IL-1, and TNFα (Th1 cytokines),3–5 with similar 
findings shown also in course of anxious states,6–8 reflecting 
a substantial psychopathological overlap.9 Recently, the 
need for further insights into the  antidepressant efficacy of 
antidepressants and the need for a better understanding of the 
putative biological bases of depression, prompted correlational 
studies  investigating the influence of  antidepressant 
medications on the immune system, both in psychiatric 
patients and the general population, and in  animals.10 To date, 
most of the immunological  investigations carried out in 
MDD patients treated with antidepressant drugs focused on 
IL-6 modifications in the course of serotonergic selective 
serotonin reuptake inhibitors (SSRIs)  treatment, which is 
still the most frequently prescribed class of antidepressants.11 
Also, while most of the evidence suggests a decrease of 
IL-6 levels in the course of SSRIs antidepressant treatment, 
global results are inconclusive, thus raising questions 
about the relationship between serotonergic-mediated 
antidepressant response and IL-6 decrease.12 Nevertheless, 
corresponding data for other classes of antidepressant 
drugs are lacking. Only preliminary evidence is available 
for the effect of venlafaxine, a serotonin norepinephrine 
reuptake inhibitor (SNRI), on IL-6 levels during the course 
of MDD,13 with increases or decreases in IL-6 essentially 
governed by the dose of drug given.13,14 Venlafaxine appears 
to have a complex action on IL-6: administered at low 
doses, it appears to reduce IL-6 serum levels, but higher 
doses (eg, $150 mg/day) seem to induce an increase in 
IL-6.13,15,16 Venlafaxine essentially acts as a pro-serotonergic, 
 SSRI-like, antidepressant at low doses, while at higher 
doses it also produces a pro-norepinephrinergic effect.17 
Thus, assessing the effect of venlafaxine on IL-6 should 
take into account the dose. Remarkably, no  equivalent 
data have been obtained to date for  duloxetine, another 
SNRI drug. Furthermore, duloxetine is supposed to act as a 
balanced (1:1), pro- serotonergic and pro- norepinephrinergic 
drug independently on its dosage,18 thus IL-6 levels upon 
duloxetine administration would be expected to follow a 
linear trend even at low doses (eg, 60 mg/day or lower).
The objective of this study was to investigate the effect of 
60 mg/day duloxetine on serum concentration of IL-6 in 16 
depressed outpatients and 16 healthy controls within a period 
of 6 weeks, with the aim of gaining a better understanding 
of the interaction between antidepressant response and IL-6 
levels.
Method
Twenty outpatients diagnosed with MDD were screened over 
12 months for inclusion in a 6-week open-label trial investigat-
ing the effect of duloxetine 60 mg/day  monotherapy on IL-6 
levels. All diagnoses were made according to the Diagnostic 
and Statistical Manual for Mental  Disorders (Fourth  Edition) 
(DSM-IV) criteria19 assessed by the Structured Clinical 
Interview for Axis-I Disorders/Patient edition (SCID-I/P).20 
At baseline, 16 patients were eligible to enter the study (3 did 
not sign the informed consent and 1 was coughing), fulfilling 
all the inclusion criteria,  including the actual presence of a 
single or recurrent, drug-naïve, major depressive episode, age 
of 18 to 65 years, and able to give a valid informed consent 
upon approval by the local  Ethical Committee. Exclusion 
criteria included the following: pregnancy, breast-feeding, 
bipolar disorder, any anxiety disorder, schizophrenia, schizo-
affective disorder, dementia, current suicidal and/or psychotic 
ideation, or concomitant taking of relevant nonpsychotropic 
medications (including other antidepressants, nonsteroidal 
anti-inflammatory drugs, and oral contraceptives). Any 
eventual concomitant medication had to be discontinued at 
least 15 days prior taking of duloxetine, 4 weeks earlier in 
case of fluoxetine or depot antipsychotics. Zolpidem 5 to 
10 mg/day or diazepam 5 to 10 mg/day were allowed, but 
could not be taken the night before scheduled assessments. 
Additional exclusion criteria included history of relevant 
medical comorbidities (ie, autoimmune, allergic, neoplastic, 
endocrine diseases, surgery, vascular stroke, or acute or 
chronic infection within the previous month). A mandatory 
inclusion criterion was the presence of a baseline total score on 
the Hamilton  Depression Scale (HAM-D) at 17 items $1821 
(responders would have to show a reduction of HAM-D score 
at week 6 $ 50% vs baseline) when undergoing a physical 
examination, standard laboratory tests, and immunological 
monitoring of IL-6. The Young Mania Rating Scale (YMRS) 
was also administered both at baseline and week 6 in order 
to assess any  eventual drug-induced (hypo)manic switch, 
defined as a total score .13.22 Blood samples were obtained at 
08.30–10.00 am, in order to limit a potential circadian 
rhythm variance bias. The whole sample was rescreened at 
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week 6 (end of the study) using HAM-D and IL-6 sampling 
(blood samples were drawn at the same time). Serum levels 
of IL-6 were measured using the instant ELISA (enzyme-
linked immunosorbent assay) method (Bender MedSystems, 
Burlingame, CA). The same clinical rating scales and labo-
ratory procedures were also applied to the healthy control 
group (n = 16) defined by a baseline HAM-D score ,7 (and 
YMRS , 12). All laboratory procedures were performed at 
the San Martino Hospital of Genoa, Italy. Over the entire trial, 
the control group received exactly the same pharmacological 
regimen (duloxetine 60 mg/day) prescribed to the depressed 
subjects.
Statistical analysis
The investigated sample included a low number of subjects. 
Baseline and week 6 HAM-D and IL-6 variables did not follow 
a normal distribution according to the Kolmogorov–Smirnov 
test, therefore requiring nonparametric tests for the  comparison 
of groups in order to assess the hypothetical validity of IL-6 
biomarker for antidepressant response to duloxetine. IL-6 
 levels of responders, nonresponders, and controls were 
compared using the Mann–Whitney U test.
Pre- and post-treatment IL-6, HAM-D, and YMRS 
values of the depressed patients and healthy controls were 
assessed using the Wilcoxon paired samples test. Correlation 
between IL-6 levels and HAM-D values between responders, 
nonresponders, and control was assessed using the Pearson 
correlation coefficient. Two-tailed tests with a 5% level of 
significance were used throughout the analyses. All statistical 
analyses were performed using IBM SPSS Statistics® Version 
19 for Windows® (SPSS, Chicago, IL).
Results
The sample (female, F = 21; male, M = 11) included 
16 MDD patients (F = 12; M = 4) with a mean baseline 
HAM-D = 20.94 ± 2.839 and YMRS = 2.12 ± 1.15 and 
16 healthy controls (F = 9; M = 7) with a mean HAM-D 
total score = 3.75 ± 1.44 and mean YMRS = 4.7 ± 2. 
Mean ages of patients and controls were 51.1 ± 11 and 
44 ± 11.6 years, respectively. No statistically significant 
differences were observed between the groups for gender 
distribution, age, or baseline HAM-D (although, by definition, 
this was higher in patients vs controls). Comparison of mean 
values of HAM-D and YMRS total scores and IL-6 mean 
values before and after the treatment in the depressed patients 
at baseline and control subjects are reported in Table 1. In the 
patients group, 14 patients (87.5%) showed a reduction in 
HAM-D total scores after treatment while 2 (12.5%) were 
unmodified; IL-6 levels increased in 11 patients (68.75%) 
and decreased in 5 (31.25%). Notably, in the patients group 
all clinical modifications in the follow-up observation were 
significant (P = 0.001), but in the nonresponders none of the 
changes in IL-6 levels were significant. In the control group, 
6 (37.5%) subjects showed a reduction in HAM-D scores, 3 
(18.75%) had an increase, and 7 (43.75%) were unmodified. 
Six (37.5%) subjects reported an increase in YMRS score, 6 
(37.5%) a reduction, while 2 (12.5%) were unmodified. Eight 
(50%) patients showed a reduction in IL-6 levels, 6 (37.5%) 
an increase, and 2 (12.5%) were substantially stable. Notably, 
none of the modifications observed in the control group was 
statistically significant, including differences in baseline 
IL-6 levels between patients and controls. No statistically 
significant correlations between HAM-D, YMRS scores, and 
IL-6 levels among responders, nonresponders and controls, 
before and after treatment, were observed except for the IL-6 
levels pre- and post-treatment in responders (P = 0.012), as 
shown in Table 2. The HAM-D (P = 0.001) and the YMRS 
(P = 0.001) mean total scores pre- and post-treatment were 
significantly different between baseline and week 6 in the 
patients group. No statistical correlations were observed 
between HAM-D and IL-6 scores at baseline in any group. 
Finally, none of the subjects enrolled in the study experienced 
adverse events or significant side effects (eg, nausea, head-
ache) that could be considered as physiological stressors that 
could have influenced the  hypothalamic–pituitary–adrena 
axis and directly or indirectly affected IL-6 levels.
Table 1 Mean values of hAM-D and YMrS total scores and IL-6 mean values before and after the treatment in the depressed patients 
at baseline and control subjects
HAM-D total score (mean ± SD) YMRS total score (mean ± SD) IL-6 levels (pg/mL) (mean ± SD)
Pre-treatment Post-treatment Pre-treatment Post-treatment Pre-treatment Post-treatment
Patients (n = 16) 20.94 ± 2.84 9.13 ± 5.8 2.13 ± 1.15 5.81 ± 1.80 12.38 ± 19.80 19.73 ± 18.94
Controls (n = 16)  3.75 ± 1.44  3.5 ± 1.34 4.69 ± 2.02 4.75 ± 2.08 12.25 ± 21.12 17.63 ± 20.44
Notes: In the patient group, the modifications in HAM-D and YMRS scores were highly significant (P = 0.001) but those in IL-6 levels were not (P = 0.215). In the control 
group, there were no significant modifications: HAM-D (P = 0.248), YMrS (P = 0.9.68) and IL-6 (P = 0.775).
Abbreviations: hAM-D, hamilton Depression rating Scale; YMrS, Young Mania rating Scale; IL-6, interleukin-6.
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Discussion
A number of issues should be considered in the interpretation 
of our results, which should be considered only preliminary 
at this time. The open design method of the study and its 
lack of power, the lack of an accurately matched control 
group, the unrepresentative sample size, and short follow-up 
significantly limit the validity of our findings. Additionally, 
IL-6 serum levels measured during the study might differ 
from those beyond the blood–brain barrier. Nevertheless, 
IL-6 levels are “dispersive” in terms of standard deviation 
even in baseline samples, both in depressed and control 
subjects, further limiting the statistical validity of our results. 
Additionally, the unexpected finding of a general increase 
in IL-6 levels after a 6-week treatment with duloxetine 
60 mg/day in responders compared with available data for 
SSRIs, the lack of larger sampled control groups including 
other classes of drugs, and/or additional arms with higher 
doses of duloxetine (eg, 120 mg/day) appear relevant, too.
After 6 weeks of treatment with duloxetine 60 mg/day, 
all subjects (both patients and controls) showed a decrease in 
HAM-D total scores and a slight increase in YMRS scores. 
None of the patients switched to mania according to YMRS 
cut-off.22 Nine of 16 patients had a preliminary response 
(actually a clinical “remission”) and a significant increase 
in IL-6 levels after 6 weeks.
Although the small sample size of this study might have 
contributed to almost the lack of statistically significant 
results, it should be noted that the increase in IL-6 levels after 
6 weeks treatment with duloxetine 60 mg/day in responders is 
an unexpected result. Indeed, the evidence for a modification 
in IL-6 levels in MDD is still a debated issue. In a pioneering 
study Maes et al, higher levels of IL-6 levels were observed in 
patients with MDD vs controls.23 Berk et al also found signifi-
cantly higher levels of IL-6 in patients with MDD.24 On the 
contrary, Kagaya et al found no significant difference in IL-6 
levels of depressed patients compared with healthy subjects.25 
Additionally, Levine et al found decreased levels of IL-6 in 
the cerebrospinal fluids of depressive patients,26 while in a 
study by Kubera et al, serum IL-6 levels of depressed patients 
were higher compared with healthy controls.27  However, this 
difference was not statistically  significant and the IL-6 levels 
of treated patients did not decrease upon recovery from 
depression.27 Lanquillon et al found an increase in mean 
IL-6 levels of responders after antidepressant treatment, 
while it remained high in nonresponders.5 Frommberger 
et al found a decrease in the IL-6 levels of depressed patients 
after treatment with antidepressants.28 De Berardis et al,12 
in a systematic review of immunological modulation in the 
course of antidepressant therapy, including venlafaxine, 
found that IL-6 levels decreased at low doses (as generally 
observed in course of treatment with SSRIs), and increased at 
higher doses. This may be hypothetically due to a differential 
serotonin/norepinephrine (5-HT/NA) balance caused by the 
drug, depending on its dosage. Indeed, both 5-HT and NA 
appear implicated in IL-6 modulation.
These evidences suggested the investigation of  duloxetine 
impact on IL-6 levels, focusing on its pro-norepinephrinergic 
properties, especially considering that current  literature 
data on other (also) pro-norepinephrinergic drugs is almost 
unavailable. Specifically, in relation to levels of  cytokines and 
their modulation after treatment with tricyclic  antidepressants 
(TCAs), some studies showed that this class of drugs 
inhibits the IL-1β, IL-2, TNF-alpha, and INF-γ (Th1-type 
cytokines)29,30 and may enhance the production of IL-10 
(Th2-type cytokines).31 Yet, studies on TCAs and IL-6 show 
discordant results: while a clinical study reported an 
increase in IL-6,13 other preclinical investigations do not.32,33 
 Furthermore, while TCAs may significantly differ from each 
other in terms of prevalent stimulation (eg, tertiary amines 
may promote 5-HT stimulation while secondary ones may 
enhance the NA-ergic transmission), the investigation of the 
effect of TCAs on IL-6 levels appears further complicated 
by the fact that these compounds have a wide range of phar-
macodynamic effects. Among other effects, TCAs show 
muscarinic (M1), adrenergic (alpha-1), and histaminergic 
(H1) blockade, potentially affecting the immune modulation. 
Also, it should be noted that desipramine, a secondary amine, 
inhibits TNF-alpha production, increasing the release of 
IL-10 and shifting the immune balance toward a Th2-like 
response.34 Regrettably, no equivalent data are available 
for most of the newer pro-NA-ergic antidepressants such 
as atomoxetine, or the studies did not focus on IL-6, as in 
the reboxetine nonclinical studies. However, a single study 
in animal cells and under specific conditions, reported that 
pretreatment with reboxetine inhibited the increase of IL-6 
due to INF-gamma exposure in the murine microglial cells.35 
Anyway, it should be remarked that the disparity of results 
from pre-clinical vs clinical studies might be due to dose 
Table 2 Modification in interleukin (IL)-6 levels before and 
after treatment in the responders group (P = 0.012) and 
nonresponders (ns)
IL-6 levels (pg/mL) (mean ± SD)
Pre-treatment Post-treatment
responder patients (n = 9; 56%)  6.89 ± 6.878 20.43 ± 20.32
Nonresponders (n = 7; 44%) 19.45 ± 28.523 18.83 ± 18.566
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and timing issues, further requiring rigorous investigations 
focusing on glucocorticoid–cathecolamine interactions.
Recent evidence indicated that both glucocorticoids and 
catecholamines (epinephrine and NA) systematically  mediate 
a Th2 shift suppressing role on Th1-cytokine (IL-12 and 
IFN-gamma) and upregulation of Th2-cytokine production 
(IL-6 and IL-10) through stimulation of  cytoplasmic–nuclear 
glucocorticoid receptors and β
2
 adrenergic receptors, 
respectively.36 Therefore, since catecholamines upregulate 
IL-6 production, the chronic hyper-noradrenergic state, 
essentially promoted by NA-ergic stimulation, may drive 
the increase in systemic IL-6 levels.2
Interestingly, baseline IL-6 levels in patients in  treatment 
remission after 6 weeks were considerably higher than in 
those ending treatment as nonresponders. Nonetheless, since 
our samples were not statistically representative and ranges 
of IL-6 levels are very wide, prudence is needed in inter-
preting our results. Nonetheless, it should be  hypothesized 
that depressed patients who will remit on 60 mg/day dulox-
etine for 6 weeks (clinically indistinguishable at baseline 
from those who will not) may exhibit lower levels of IL-6 at 
baseline which in turn may “predict” a favorable response to 
treatment with duloxetine 60 mg/day for 6 weeks. It could be 
therefore hypothesized that the presence of lower levels of 
IL-6 at baseline among depressed (but not healthy controls) 
may be due to hypo-noradrenergic activity which may pref-
erentially benefit from the pro-norepinephrinergic action 
induced by duloxetine, which in turn may “normalize” the 
IL-6 levels in this subgroup via Th2 shift mediated by NA. 
Indeed, much prudence as well as larger-sample controlled 
studies, including proxy measurements of sympathetic–
norepinephrinergic activity at baseline and endpoint are 
warranted prior to extending such hypothesis.  Nonetheless, 
similar f indings were already reported by Lanquillon 
et al5  regarding pre- and post-treatment IL-6 levels among 
responders and nonresponders. In this study, the authors found 
that  subjects beginning the treatment in presence of lower 
baseline IL-6 levels were less prone to significant increase for 
this  parameter after the trial, resembling our finding in that 
regard, thus suggesting that IL-6 levels “might dichotomize 
the patients into subsequent responders and nonresponders” 
prior the initiation of the therapeutic regimen.
If these results could be confirmed by more rigorous 
investigations, it may be hypothesized that the balance 
5-HT/NA may modulate the levels of IL-6. Consequently, 
IL-6 levels could be considered a potential marker of the 
Th1/Th2 balance. If this hypothesis can be confirmed by more 
rigorous study, we could say that the greater the  NA-ergic 
component of antidepressant, the higher the shift of the 
Th1/Th2 balance toward a Th2-type response.
Elucidating the effect of 5-HT/NA and Th1/Th2 balances 
on IL-6 levels and demonstrating IL-6 levels as a reliable 
marker of antidepressant response, may lead to further 
insights into the understanding of the pathophysiology of 
depression and antidepressant response even for classes of 
drugs different from the proven clinically effective, mainly 
serotonergic agents.
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